Statins as Pleiotropic Modifiers of Vascular Oxidative Stress and Inflammation

被引:5
作者
Psarros, Costas [1 ]
Economou, Evangelos K. [1 ]
Koutsilieris, Michael [1 ]
Antoniades, Charalambos [2 ]
机构
[1] Univ Athens, Sch Med, Dept Expt Physiol, Athens, Greece
[2] Univ Oxford, John Radcliffe Hosp, Radcliffe Dept Med, Div Cardiovasc Med, West Wing L6,Headley Way, Oxford OX3 9DU, England
关键词
atherosclerosis; adhesion molecules; cardiovascular disease; interleukins; inflammation; oxidative stress; statins;
D O I
10.1515/jccm-2015-0007
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the industrialized world and in the future is expected to be the number one killer worldwide. The main cause underlying CVD is atherosclerosis. A key event in atherosclerosis initiation and progression is oxidative stress through the production of reactive oxygen species as well as endothelial dysfunction. Several pro-inflammatory and anti-inflammatory cytokines and proteins are involved in this process, complemented by activation of adhesion molecules that promote leukocyte rolling, tethering and infiltration into the sub-endothelial space. Statins represent the agent of choice since numerous clinical trials have verified that their pharmacological action extends beyond lipid lowering. Statins demonstrate direct anti-oxidant effects by scavenging free radicals and stimulating anti-oxidant enzymes while acting as regulators for cytokine, protein and adhesion molecule expression, all of which are involved in the atherosclerotic process. Statin use is considered one of the most efficient currently used interventions in managing CVD with the likely hood of remaining so in the near future.
引用
收藏
页码:43 / 54
页数:12
相关论文
共 85 条
  • [61] Nanomedicine for the prevention, treatment and imaging of atherosclerosis
    Psarros, Costas
    Lee, Regent
    Margaritis, Marios
    Antoniades, Charalambos
    [J]. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2012, 8 : S59 - S68
  • [62] Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients
    Rezaie-Majd, A
    Maca, T
    Bucek, RA
    Valent, P
    Müller, MR
    Husslein, P
    Kashanipour, A
    Minar, E
    Baghestanian, M
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (07) : 1194 - 1199
  • [63] Rho YH, 2008, J RHEUMATOL, V35, P1789
  • [64] Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
    Ridker, Paul M.
    Danielson, Eleanor
    Fonseca, Francisco A. H.
    Genest, Jacques
    Gotto, Antonio M., Jr.
    Kastelein, John J. P.
    Koenig, Wolfgang
    Libby, Peter
    Lorenzatti, Alberto J.
    MacFadyen, Jean G.
    Nordestgaard, Borge G.
    Shepherd, James
    Willerson, James T.
    Glynn, Robert J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (21) : 2195 - 2207
  • [65] Rifai N, 2001, CLIN CHEM, V47, P28
  • [66] Romano M, 2000, J INVEST MED, V48, P183
  • [67] IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines
    Schmitz, J
    Owyang, A
    Oldham, E
    Song, YL
    Murphy, E
    McClanahan, TK
    Zurawski, G
    Moshrefi, M
    Qin, JZ
    Li, XX
    Gorman, DM
    Bazan, JF
    Kastelein, RA
    [J]. IMMUNITY, 2005, 23 (05) : 479 - 490
  • [68] How much is too much? Interleukin-6 and its signalling in atherosclerosis
    Schuett, Harald
    Luchtefeld, Maren
    Grothusen, Christina
    Grote, Karsten
    Schieffer, Bernhard
    [J]. THROMBOSIS AND HAEMOSTASIS, 2009, 102 (02) : 215 - 222
  • [69] Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease
    Seljeflot, I
    Tonstad, S
    Hjermann, I
    Arnesen, H
    [J]. ATHEROSCLEROSIS, 2002, 162 (01) : 179 - 185
  • [70] Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA):: a multicentre randomised controlled trial
    Sever, PS
    Dahlöf, B
    Poulter, NR
    Wedel, H
    Beevers, G
    Caulfield, M
    Collins, R
    Kjeldsen, SE
    Kristinsson, A
    McInnes, GT
    Mehlsen, J
    Nieminen, M
    O'Brien, E
    Östergren, J
    [J]. LANCET, 2003, 361 (9364) : 1149 - 1158